These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15634649)

  • 21. Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies.
    Iwano J; Shinmi D; Masuda K; Murakami T; Enokizono J
    Drug Metab Dispos; 2019 Nov; 47(11):1240-1246. PubMed ID: 31533926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinoembryonic antigen and alpha-fetoprotein expression and monoclonal antibody targeting in a human hepatoma/nude mouse model.
    Wang ZF; Stein R; Sharkey RM; Goldenberg DM
    Cancer Res; 1990 Feb; 50(3 Suppl):869s-872s. PubMed ID: 1688735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
    Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
    Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model.
    Hekman MCH; Rijpkema M; Bos DL; Oosterwijk E; Goldenberg DM; Mulders PFA; Boerman OC
    J Nucl Med; 2017 May; 58(5):706-710. PubMed ID: 28126888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
    Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
    Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
    Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
    Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor localization of CEA-containing human tumors in nude mice by means of monoclonal anti-CEA antibodies.
    Hedin A; Wahren B; Hammarström S
    Int J Cancer; 1982 Nov; 30(5):547-52. PubMed ID: 7152719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice.
    Buchegger F; Haskell CM; Schreyer M; Scazziga BR; Randin S; Carrel S; Mach JP
    J Exp Med; 1983 Aug; 158(2):413-27. PubMed ID: 6886623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates.
    Carcenac M; Larroque C; Langlois R; van Lier JE; Artus JC; Pèlegrin A
    Photochem Photobiol; 1999 Dec; 70(6):930-6. PubMed ID: 10628305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immunohistochemical study on 79 thyroid lesions.
    Komminoth P; Roth J; Saremaslani P; Matias-Guiu X; Wolfe HJ; Heitz PU
    Am J Surg Pathol; 1994 Apr; 18(4):399-411. PubMed ID: 8141431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
    Orlandi F; Caraci P; Berruti A; Puligheddu B; Pivano G; Dogliotti L; Angeli A
    Ann Oncol; 1994 Oct; 5(8):763-5. PubMed ID: 7826911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carcinoembryonic antigen expression of resurgent human colon carcinoma after treatment with therapeutic doses of 90Y-alpha-carcinoembryonic antigen monoclonal antibody.
    Esteban JM; Kuhn JA; Felder B; Wong JY; Battifora H; Beatty JD; Wanek PM; Shively JE
    Cancer Res; 1991 Jul; 51(14):3802-6. PubMed ID: 2065334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
    J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
    Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Kang S; Kim SY; Hong YS; Kim TW; Choi KE; Kim MJ; Kim JE
    Sci Rep; 2023 Apr; 13(1):6735. PubMed ID: 37185297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
    Strock CJ; Park JI; Rosen DM; Ruggeri B; Denmeade SR; Ball DW; Nelkin BD
    J Clin Endocrinol Metab; 2006 Jan; 91(1):79-84. PubMed ID: 16263812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.